The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.
Secord AA, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Pérez MJR, Bonaventura A, Diver EJ, Ayuk SA, Wang Y, Corr BR, Salutari V.
Secord AA, et al. Among authors: perez mjr.
Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.11.011. Online ahead of print.
Ann Oncol. 2024.
PMID: 39617145